Recent Analysts’ Ratings Changes for Bristol-Myers Squibb (BMY)

Posted by ABMN Staff on Nov 14th, 2024

Several analysts have recently updated their ratings and price targets for Bristol-Myers Squibb (NYSE: BMY):

11/13/2024 – Bristol-Myers Squibb was upgraded by analysts at Daiwa Capital Markets from a “neutral” rating to an “outperform” rating.
11/12/2024 – Bristol-Myers Squibb had its price target raised by analysts at Morgan Stanley from $36.00 to $39.00. They now have an “underweight” rating on the stock.
11/12/2024 – Bristol-Myers Squibb was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating.
11/12/2024 – Bristol-Myers Squibb was upgraded by analysts at Leerink Partners from a “market perform” rating to an “outperform” rating. They now have a $73.00 price target on the stock, up previously from $55.00.
11/12/2024 – Bristol-Myers Squibb had its price target raised by analysts at Citigroup Inc. from $55.00 to $60.00. They now have a “neutral” rating on the stock.
11/12/2024 – Bristol-Myers Squibb had its price target raised by analysts at BMO Capital Markets from $57.00 to $61.00. They now have a “market perform” rating on the stock.
11/1/2024 – Bristol-Myers Squibb had its price target raised by analysts at BMO Capital Markets from $53.00 to $57.00. They now have a “market perform” rating on the stock.
10/25/2024 – Bristol-Myers Squibb was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $55.00 price target on the stock, down previously from $75.00.
10/18/2024 – Bristol-Myers Squibb had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
10/17/2024 – Bristol-Myers Squibb is now covered by analysts at Sanford C. Bernstein. They set a “market perform” rating and a $56.00 price target on the stock.
10/9/2024 – Bristol-Myers Squibb had its price target raised by analysts at UBS Group AG from $50.00 to $54.00. They now have a “neutral” rating on the stock.
10/7/2024 – Bristol-Myers Squibb had its price target raised by analysts at Barclays PLC from $42.00 to $43.00. They now have an “underweight” rating on the stock.
10/7/2024 – Bristol-Myers Squibb had its price target raised by analysts at TD Cowen from $53.00 to $59.00. They now have a “hold” rating on the stock.
9/23/2024 – Bristol-Myers Squibb had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $48.00 price target on the stock.
9/16/2024 – Bristol-Myers Squibb had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.

Bristol-Myers Squibb Trading Down 1.0 %

NYSE BMY opened at $58.43 on Thursday. The firm has a market capitalization of $118.51 billion, a PE ratio of -16.28, a P/E/G ratio of 21.34 and a beta of 0.44. The stock’s 50 day moving average is $52.24 and its 200 day moving average is $46.99. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.08. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion for the quarter, compared to analysts’ expectations of $11.26 billion. During the same period in the previous year, the firm posted $2.00 EPS. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. Research analysts forecast that Bristol-Myers Squibb will post 0.92 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 annualized dividend and a yield of 4.11%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -66.85%.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the transaction, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Samit Hirawat acquired 1,830 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, November 1st. The stock was bought at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the transaction, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the firm’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Meridian Management Co. raised its stake in Bristol-Myers Squibb by 0.6% during the 3rd quarter. Meridian Management Co. now owns 28,283 shares of the biopharmaceutical company’s stock worth $1,463,000 after acquiring an additional 182 shares during the period. Hollencrest Capital Management increased its stake in shares of Bristol-Myers Squibb by 61.3% in the third quarter. Hollencrest Capital Management now owns 492 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 187 shares in the last quarter. Mayflower Financial Advisors LLC raised its position in shares of Bristol-Myers Squibb by 2.3% during the 3rd quarter. Mayflower Financial Advisors LLC now owns 8,466 shares of the biopharmaceutical company’s stock valued at $438,000 after purchasing an additional 192 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its stake in shares of Bristol-Myers Squibb by 3.8% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 5,595 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 206 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC boosted its holdings in Bristol-Myers Squibb by 2.1% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 10,288 shares of the biopharmaceutical company’s stock worth $532,000 after buying an additional 215 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.